| Assessment Status | Assessment process complete |
| HTA ID | 19050 |
| Drug | Larotrectinib |
| Brand | Vitrakvi® |
| Indication | For patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion. |
| Assessment Process | |
| Rapid review completed | 13/01/2020 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of larotrectinib compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 20/01/2020 |
| Pre-submission consultation with Applicant | 20/04/2020 |
| Full submission received from Applicant | 11/02/2021 |
| Preliminary review sent to Applicant | 16/07/2021 |
| NCPE assessment re-commenced | 30/08/2021 |
| Follow-up to preliminary review sent to Applicant | 10/09/2021 |
| NCPE assessment re-commenced | 15/09/2021 |
| Additional follow-up to Preliminary Review sent to Applicant | 05/10/2021 |
| NCPE assessment re-commenced | 13/10/2021 |
| Factual accuracy sent to applicant | 22/10/2021 |
| NCPE assessment re-commenced | 03/11/2021 |
| NCPE assessment completed | 23/11/2021 |
| NCPE assessment outcome | The NCPE recommends that larotrectinib (Vitrakvi®) not be recommended for reimbursement, unless cost effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013
